Autres langues Intervacc AB

Actions

IVACC

SE0009607252

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 20/07/2026			Varia. 5j.	Varia. 1 janv.
1,162 ^SEK	-0,34%		-10,48%	+25,76%

22/05	Intervacc AB achève avec succès l'évaluation d'une souche américaine de la gourme avant les essais cliniques	CI
15/05	Suède : Intervacc élit son nouveau président	MT

Autres langues

04/06	Redeye initiates coverage of Intervacc
22/05	Intervacc: Positive results
22/05	Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials
22/05	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials
15/05	Intervacc: US progress, while European sales still soft – Q1 review
15/05	Sweden's Intervacc Elects New Chair
15/05	Appoints Emil Billbäck as chairman
15/05	Emil Billbäck appointed new Chair of the Board of Intervacc
13/05	Intervacc elects Emil Billbäck as chairperson of board
13/05	Report from Annual General Meeting in Intervacc
13/05	Intervacc AB Announces Board Changes
13/05	Intervacc Q1 net sales down at SEK 3.4 million
13/05	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	Intervacc strengthens management team for future growth
12/05	Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026
04/05	International Awareness Initiative Against Strangles
23/04	Intervacc brings together leading US and European experts to jointly tackle strangles
16/04	Intervacc: Strangvac vaccine approved in Iceland
16/04	Unprecedented decision opens the way for the launch of Strangvac in Iceland
16/04	Intervacc AB Announces Approval and Launch of Strangvac Vaccine in Iceland
14/04	Intervacc publishes the 2025 Annual Report
10/04	Notice of Annual General Meeting in Intervacc AB (publ)
20/03	Intervacc: Highly promising data presented
19/03	Intervacc announces breakthrough protection against Streptococcus suis infection in piglets
19/03	Intervacc AB Publ Announces Breakthrough Protection Against Streptococcus Suis Infection in Piglets